GU Cancers Symposium 2020: Apalutamide and Time to Second Progression in Patients With Prostate Cancer
Posted: Tuesday, February 25, 2020
The randomized phase III TITAN study found that apalutamide plus androgen-deprivation therapy significantly improved survival outcomes for patients with metastatic castration-sensitive prostate cancer compared with those treated with a placebo. In a post-hoc analysis, Neeraj Agarwal, MD, of the University of Utah, Salt Lake City, and colleagues found that, regardless of whether the first life-prolonging subsequent therapy was hormonal or a taxane, apalutamide plus androgen-deprivation therapy reduced the time to second progression compared with a placebo. The findings were presented at the 2020 Genitourinary (GU) Cancers Symposium in San Francisco (Abstract 82).
Of the 277 eligible patients who received subsequent therapy for prostate cancer, 86 were treated with hormonal therapy and 99 were treated with taxane therapy. Of those who received hormonal therapy, 24 patients received apalutamide and 62 received a placebo. Among the patients treated with taxane therapy, 30 patients received apalutamide and 69 received a placebo.
Among patients in the hormonal group, the median treatment duration with apalutamide and placebo was 11.9 months and 11.1 months, respectively. For those patients who received subsequent taxane therapy, the median treatment duration with apalutamide and placebo was 11.0 months and 11.3 months, respectively.
The study group found that, regardless of the subsequent systemic therapy received, patients in the apalutamide arm achieved a longer time to second progression than patients in the placebo arm (P = .0026). In both groups, those patients who received apalutamide also had a significantly reduced risk of second progression than those in the placebo group (P < .05). The researchers did not conduct safety analyses. All patients discontinued therapy, most as a result of disease progression.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
